WO2002031209A3 - Genes related to development of refractory prostate cancer - Google Patents
Genes related to development of refractory prostate cancer Download PDFInfo
- Publication number
- WO2002031209A3 WO2002031209A3 PCT/US2001/031932 US0131932W WO0231209A3 WO 2002031209 A3 WO2002031209 A3 WO 2002031209A3 US 0131932 W US0131932 W US 0131932W WO 0231209 A3 WO0231209 A3 WO 0231209A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- refractory prostate
- prostate cancer
- development
- hormone
- genes related
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Hospice & Palliative Care (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2002214576A AU2002214576A1 (en) | 2000-10-13 | 2001-10-12 | Genes related to development of refractory prostate cancer |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US24058500P | 2000-10-13 | 2000-10-13 | |
US60/240,585 | 2000-10-13 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2002031209A2 WO2002031209A2 (en) | 2002-04-18 |
WO2002031209A3 true WO2002031209A3 (en) | 2003-08-28 |
Family
ID=22907131
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2001/031932 WO2002031209A2 (en) | 2000-10-13 | 2001-10-12 | Genes related to development of refractory prostate cancer |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU2002214576A1 (en) |
WO (1) | WO2002031209A2 (en) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020142327A1 (en) * | 2000-11-28 | 2002-10-03 | Gillis Kimberly A. | Expression analysis of smarc nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer |
NZ526708A (en) | 2000-11-28 | 2005-07-29 | Wyeth Corp | Expression analysis of FKBP nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer |
US20030235816A1 (en) * | 2002-03-14 | 2003-12-25 | Baylor College Of Medicine (By Slawin And Shariat) | Method to determine outcome for patients with prostatic disease |
TW200413539A (en) * | 2002-09-30 | 2004-08-01 | Oncotherapy Science Inc | Genes and polypeptides relating to prostate cancers |
ITBZ20020040A1 (en) * | 2002-10-11 | 2004-04-12 | Saverio Bettuzzi | METHOD FOR IDENTIFICATION THROUGH THE DESIGN AND USE OF APPROPRIATE MICROCHIP -DNA MICROARRAY OF THE TUMOR TRANSFORMATION OF THE PROSTATIC TISSUE, ASSESSMENT OF ITS MALIGNITY AND PROGNOSIS OF HUMAN PROSTATIC CANCER BY A NEW ME |
GB0227908D0 (en) | 2002-11-29 | 2003-01-08 | Univ London | Cancer related methods and means |
WO2005083118A2 (en) * | 2004-02-27 | 2005-09-09 | Oncotherapy Science, Inc. | Pin-prc transition genes |
EP1737980A2 (en) | 2004-04-09 | 2007-01-03 | Fondazione IRCCS Istituto Nazionale dei Tumori | Gene expression markers for predicting response to chemotherapy |
EP2311984A1 (en) * | 2004-12-02 | 2011-04-20 | Epigenomics AG | Methods and nucleic acids for the analysis of gene expression associated with the prognosis of prostate cell proliferative disorders |
EP2405022A3 (en) * | 2008-07-08 | 2012-05-02 | Genomic Health, Inc. | Gene expression profiling for predicting the survivability of prostate cancer subjects |
WO2010093872A2 (en) | 2009-02-13 | 2010-08-19 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Molecular-based method of cancer diagnosis and prognosis |
EP2913405B1 (en) | 2010-07-27 | 2016-11-09 | Genomic Health, Inc. | Method for using gene expression to determine prognosis of prostate cancer |
JP2012178990A (en) * | 2011-02-28 | 2012-09-20 | Soka Univ | Method for detecting recurrent prostate cancer |
CN102234632B (en) * | 2011-04-29 | 2014-05-14 | 南方医科大学 | Hybrid tumor DY01 of monoclonal antibody of human ubiquitin-conjugating enzyme UbcH10, and monoclonal antibody |
CN102234631B (en) * | 2011-04-29 | 2014-05-07 | 南方医科大学 | Human ubiquitin-conjugating enzyme UbcH10 monoclonal antibody hybrid tumor DY03 and monoclonal antibody |
CN102234633B (en) * | 2011-04-29 | 2014-05-07 | 南方医科大学 | Human ubiquitin-conjugating enzyme UbcH10 monoclonal antibody hybrid tumor DY02 and monoclonal antibody |
JP6351112B2 (en) | 2012-01-31 | 2018-07-04 | ジェノミック ヘルス, インコーポレイテッド | Gene expression profile algorithms and tests to quantify the prognosis of prostate cancer |
US20150329912A1 (en) * | 2013-01-13 | 2015-11-19 | Emory University | Biomarkers in cancer, methods, and systems related thereto |
GB201322034D0 (en) | 2013-12-12 | 2014-01-29 | Almac Diagnostics Ltd | Prostate cancer classification |
WO2018022917A1 (en) * | 2016-07-27 | 2018-02-01 | Protagonist Therapeutics, Inc. | Disulfide-rich peptide libraries and methods of use thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998056910A1 (en) * | 1997-06-11 | 1998-12-17 | Chiron Corporation | DETECTION OF LOSS OF THE WILD-TYPE huBUB1 GENE |
WO1999066051A2 (en) * | 1998-06-16 | 1999-12-23 | Sugen, Inc. | Nek-related and bub1-related protein kinases |
-
2001
- 2001-10-12 AU AU2002214576A patent/AU2002214576A1/en not_active Abandoned
- 2001-10-12 WO PCT/US2001/031932 patent/WO2002031209A2/en active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998056910A1 (en) * | 1997-06-11 | 1998-12-17 | Chiron Corporation | DETECTION OF LOSS OF THE WILD-TYPE huBUB1 GENE |
WO1999066051A2 (en) * | 1998-06-16 | 1999-12-23 | Sugen, Inc. | Nek-related and bub1-related protein kinases |
Non-Patent Citations (7)
Title |
---|
BUBENDORF L ET AL: "HORMONE THERAPY FAILURE IN HUMAN PROSTATE CANCER: ANALYSIS BY COMPLEMENTARY DNA AND TISSUE MICROARRAYS", JOURNAL OF THE NATIONAL CANCER INSTITUTE, US DEPT. OF HEALTH, EDICATIONAND WELFARE, PUBLIC HEALTH, US, vol. 91, no. 20, 20 October 1999 (1999-10-20), pages 1758 - 1764, XP002934471, ISSN: 0027-8874 * |
CARLISLE ALEX J ET AL: "Development of a prostate cDNA microarray and statistical gene expression analysis package.", MOLECULAR CARCINOGENESIS, vol. 28, no. 1, May 2000 (2000-05-01), pages 12 - 22, XP002225396, ISSN: 0899-1987 * |
HOWELL S ET AL.: "DNA microarrays for analysis of gene expression in prostate cancer", MOLECULAR UROLOGY, vol. 3, no. 3, 1999, pages 295 - 302, XP001131993 * |
MOUSSES S ET AL: "Functionnal genomics : gene expression analysis by cDNA microarrays", 2000, LIVESEY FJ AND HUNT SP (EDS) OXFORD UNIVERSITY PRESS, OXFORD, XP008011769 * |
MOUSSES SPYRO ET AL: "Failure of hormone therapy in prostate cancer involves systematic restoration of androgen responsive genes and activation of rapamycin sensitive signaling.", ONCOGENE, vol. 20, no. 46, 11 October 2001 (2001-10-11), pages 6718 - 6723, XP001132000, ISSN: 0950-9232 * |
NAKAJIMA HIDENORI ET AL: "New antitumor substances, FR901463, FR901464 and FR901465: II. Activities against experimental tumors in mice and mechanism of action.", JOURNAL OF ANTIBIOTICS (TOKYO), vol. 49, no. 12, 1996, pages 1204 - 1211, XP001109403, ISSN: 0021-8820 * |
VAARALA M H ET AL: "Differentially expressed genes in two LNCaP prostate cancer cell lines", LABORATORY INVESTIGATION;A JOURNAL OF TECHNICAL METHODS AND PATHOLOGY. UNITED STATES AUG 2000, vol. 80, no. 8, August 2000 (2000-08-01), pages 1259 - 1268, XP002225395, ISSN: 0023-6837 * |
Also Published As
Publication number | Publication date |
---|---|
WO2002031209A2 (en) | 2002-04-18 |
AU2002214576A1 (en) | 2002-04-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2002031209A3 (en) | Genes related to development of refractory prostate cancer | |
WO1999064576A3 (en) | Human genes differentially expressed in colon cancer | |
WO2001072962A3 (en) | Novel prostate-specific or testis-specific nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods | |
MXPA03003281A (en) | Non-invasive enzyme screen for tissue remodelling-associated conditions. | |
WO2003009814A3 (en) | Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of prostate cancer | |
WO2004031411A3 (en) | Genes and polypeptides relating to human pancreatic cancers | |
EA200501772A1 (en) | METHODS OF MEASURING THE EXPRESSION OF GENES FROM FIXED AND PARULIN FABRIC SAMPLE | |
MXPA02011656A (en) | Nrg 2 nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods. | |
WO2003004989A3 (en) | Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer | |
WO2003021227A3 (en) | Methods and compositions useful for diagnosis, staging, and treatment of cancers and tumors | |
WO1998035693A3 (en) | Detection and modulation of the iaps and naip for the diagnosis and treatment of proliferative disease | |
WO2000028090A3 (en) | Diagnostic assay for cancer | |
WO2002029086A3 (en) | Nucleic acid sequences differentially expressed in cancer tissue | |
WO2005062977A3 (en) | Prostate cancer specific internalizing human antibodies | |
WO2004056874A3 (en) | Neuropilin-1 inhibitors | |
WO2004106495A3 (en) | Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer | |
WO2003000012A3 (en) | Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast and ovarian cancer | |
AU2740100A (en) | A novel, prostate-specific gene for diagnosis, prognosis and management of prostate cancer | |
WO2002022879A3 (en) | Detection of microsatellite instability and its use in diagnosis of tumors | |
WO1999064594A8 (en) | Genes and gene expression products that are differentially regulated in prostate cancer | |
WO2004031231A3 (en) | Genes and polypeptides relating to prostate cancers | |
WO2002064839A3 (en) | Methods for the diagnosis and treatment of tumors employing the hepsin gene | |
ATE491951T1 (en) | TUMOR-SPECIFIC P450 PROTEIN | |
WO2002077176A3 (en) | Aberrantly expressed proteins in laser capture microdissected tumors | |
WO2003044161A3 (en) | Gene amplification and overexpression in cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |